ANRO vs. MNKD, MIRM, PRTA, CALT, ARCT, ABCL, DAWN, LQDA, IRWD, and COLL
Should you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include MannKind (MNKD), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Calliditas Therapeutics AB (publ) (CALT), Arcturus Therapeutics (ARCT), AbCellera Biologics (ABCL), Day One Biopharmaceuticals (DAWN), Liquidia (LQDA), Ironwood Pharmaceuticals (IRWD), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical preparations" industry.
Alto Neuroscience (NYSE:ANRO) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.
MannKind received 566 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 59.87% of users gave MannKind an outperform vote.
MannKind has a net margin of 3.78% compared to Alto Neuroscience's net margin of 0.00%. Alto Neuroscience's return on equity of 0.00% beat MannKind's return on equity.
49.6% of MannKind shares are owned by institutional investors. 3.0% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Alto Neuroscience had 1 more articles in the media than MannKind. MarketBeat recorded 3 mentions for Alto Neuroscience and 2 mentions for MannKind. Alto Neuroscience's average media sentiment score of 0.33 beat MannKind's score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the media.
MannKind has higher revenue and earnings than Alto Neuroscience.
Alto Neuroscience currently has a consensus price target of $32.33, indicating a potential upside of 161.60%. MannKind has a consensus price target of $8.00, indicating a potential upside of 79.37%. Given Alto Neuroscience's higher possible upside, research analysts plainly believe Alto Neuroscience is more favorable than MannKind.
Summary
Alto Neuroscience and MannKind tied by winning 7 of the 14 factors compared between the two stocks.
Get Alto Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alto Neuroscience Competitors List
Related Companies and Tools
